Protagen is able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy, helping pharmaceutical and biotech companies develop safer, more effective immunotherapies.
Predicting and detecting immune-related Adverse Events (irAEs)
Despite the enormous potential of cancer immunotherapy, many patients receiving such treatments experience debilitating and sometimes-fatal irAEs. Characterized by an over-activation of the immune system, irAEs pose a significant barrier to immunotherapy success, as they have led to the FDA halting clinical trials—slowing the development of effective cancer immunotherapies.
IrAEs closely resemble autoimmune diseases (both result from the overstimulation of the immune system). Protagen is uniquely positioned, as an autoimmune and immuno-oncology leader, to develop precision diagnostic tools that enable irAE prediction, as well the longitudinal detection of late-onset irAEs and the monitoring of irAE resolution.
In the case study below (taken from the immuno-oncology eBook), SeroTag® has been used to demonstrate that autoantibodies detected in the serum of prostate cancer patients are differentially expressed in those that develop irAEs compared to those who do not (see figures A and B). This demonstrates the significant role that autoantibodies have to play in the prediction and monitoring of irAEs, not just in prostate cancer but also in numerous other indications.
For more information on this application, and on how autoantibodies can bolster cancer immunotherapy development, download the eBook.
Predicting treatment response and overall survival
Immunotherapies such as therapeutic vaccination and checkpoint inhibition hold great promise for treating and potentially even curing cancer, but currently work effectively for only a limited number of patients. Response prediction is crucial for developing effective cancer immunotherapies, meeting regulatory standards and safeguarding patients. Being able to predict treatment response will allow clinicians to make more informed and safer decisions for patients, and will avoid the treatment of patients who do not stand to benefit from the therapy in the first place.
Protagen has shown that autoantibodies can be used as biomarkers for predicting the onset of harmful irAEs, and new research findings also suggest that autoantibodies can predict therapeutic response in patients undergoing cancer immunotherapy. The figure below (taken from the immuno-oncology eBook) shows that the pre-treatment autoantibody level has the potential to predict overall survival in prostate cancer patients. This demonstrates the significant role that autoantibodies play in the prediction of overall survival, not just in prostate cancer but in numerous other indications.
To find out more about how autoantibodies can be used to predict therapeutic outcomes, read the immuno-oncology eBook.
Protagen is dedicated to the development of precision medicine tools that are giving pharmaceutical and biotech companies the power to develop safer anti-cancer drugs, and enabling clinicians to select the right therapy for the right patient.
Protagen is expanding its NavigAID offering to support the development of immunotherapeutic anticancer drugs, owing to the role played by autoantibodies in cancer as well as autoimmune disease.
SeroTag® is Protagen’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.